# US 9,750,790 B2 · Anti-Mycoplasma spp. subunit vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,790 B2
- Document ID: US9750790B2
- Status: Granted
- Kind: B2
- Application number: 15/383,962
- Filed: 2016-12-19
- Published: 2017-06-01
- Granted: 2017-09-05
- Earliest claimed: 2016-12-19
- Assignees: Agricultural Technology Research Institute
- Applicants: Agricultural Technology Research Institute
- Inventors: Jiunn-Horng Lin; Jyh-Perng Wang; Ming-Wei Hsieh; Zeng-Weng Chen; Chien-Yu Fang; Hsueh-Tao Liu; Ping-Cheng Yang
- Web page: https://patentgrep.com/patent/US9750790B2

## CPC

- A61K 39/0241: {Mollicutes, e.g. Mycoplasma, Erysipelothrix}
- A61K 39/0208: {Specific bacteria not otherwise provided for}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- C07K 14/30: from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.

## Claims

### Claim 1

A composition for preventing a disease caused by Mycoplasma spp., comprising:
an active ingredient, comprising a protein of XylF; and
a pharmaceutically acceptable adjuvant;
wherein said XylF comprises the sequence of SEQ ID NO: 09.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said active ingredient is of a concentration of 50 to 3500 μg/mL based on the total volume of said composition.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said pharmaceutically acceptable adjuvant is a complete Freund's adjuvant, an incomplete Freund's adjuvant, an alumina gel, a surfactant, a polyanion adjuvant, a peptide, an oil emulsion, or a combination thereof.

### Claim 4 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable additive.

### Claim 5 (depends on 4)

The composition of claim 4, wherein said pharmaceutically acceptable additive is a solvent, a stabilizer, a diluent, a preservative, an antibacterial agent, an antifungal agent, an isotonic agent, a absorption delaying agent, or a combination thereof.